CORDIS · 190160766 · HORIZON
ProSpace BioProtect Balloon Implant System – Enabling Safe Prostate Radiation Treatment even at extreme dosage
Coordinator: BIOPROTECT LTD (IL)
Prostate is the 2nd leading cancer in men in the world, with more than 1.4 million men diagnosed every year globally. ~50% of men will be treated with radiation treatment. Radiation is a highly effective treatment; however, it has significant complications, mainly injuring the rectal tissue, approximate to the prostate treatment area. Up to 35% of the patients will experience rectal toxicity side effects such as bleeding, urinary, bowl and erectile dysfunction, damaging severely patient’s quality of life. There is a growing need for a solution that protects the rectum from the radiation field…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €2.5M awarded to the consortium. The project runs over approximately 2 years from 2023-10-01 to 2025-09-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from IL
see all →- CloudCT — Climate CT- Cloud Tomography by Satellites for Better Climate Prediction810370 · H2020 · €13.9M
- LUCIA — Understanding Lung Cancer related risk factors and their Impact101096473 · HORIZON · €13.5M
- D2Smell — Digitising Smell: From Natural Statistics of Olfactory Perceptual Space to Digital Transmission of Odors101118977 · HORIZON · €11.8M
- SIIP — Speaker Identification Integrated Project607784 · FP7 · €10.5M
- SAVEME — A Modular Nanosystems Platform for Advanced Cancer Management: Nano-vehicles; Tumor Targeting and Penetration Agents; Molecular Imaging, Degradome based Therapy263307 · FP7 · €10.5M
- CATO — CATO - CBRN crisis management: Architecture, Technologies and Operational Procedures261693 · FP7 · €10.3M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-EIC-ACC-BF funding scheme.
- What is the EU contribution?
- The European Commission contributes €2.5M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-EIC-2023-ACCELERATOR-01.
- Who coordinates the project?
- The project is coordinated by BIOPROTECT LTD (IL).
- What is the project timeline?
- The project runs from 2023-10-01 to 2025-09-30 — approximately 2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 190160766.